{"id":"W3172838457","doi":"10.1200/jco.2021.39.15_suppl.tps2670","title":"A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Tolerability; Pembrolizumab; Stimulator of interferon genes; Oncology; Agonist; Internal medicine; Immunotherapy; Sting; Immune system; Pharmacology; Cancer; Immunology; Innate immune system; Adverse effect; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001351492,0.0001760777,0.001541507,0.0002560781,0.00004689073,0.00001085677,0.0001317054,0.0001743163,0.00004972055],"category_scores_gemma":[0.00203417,0.0001179208,0.00006733207,0.0002693747,0.0002249514,0.0001814504,0.00006003559,0.0007647464,0.000001644068],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00010617,"about_ca_system_score_gemma":0.001140777,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003938399,"about_ca_topic_score_gemma":0.001162142,"domain_scores_codex":[0.9957844,0.00126208,0.002359662,0.0002416651,0.000106339,0.0002458516],"domain_scores_gemma":[0.9957821,0.001577764,0.001938259,0.0001479562,0.0005064546,0.00004745616],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5317482,0.1463312,0.09683262,0.0001481334,0.001356549,0.001563276,0.006420321,0.0002001094,0.02947064,0.00005527981,0.00003712673,0.1858365],"study_design_scores_gemma":[0.2245604,0.2379243,0.5273902,0.000516579,0.0002564994,0.0008601063,0.004777239,0.0001013925,0.003127227,0.00002064029,0.000253647,0.0002117178],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986883,0.000187846,0.0001807095,0.0002074402,0.0002229429,0.0004374338,0.000007264938,0.000004140887,0.00006391644],"genre_scores_gemma":[0.9988875,0.00003987673,0.0008109501,0.0001136294,0.00001224038,0.00001036557,0.00001658488,0.00001566553,0.0000932119],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4305576,"threshold_uncertainty_score":0.4808672,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07458423942254296,"score_gpt":0.4116550165163493,"score_spread":0.3370707770938064,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}